



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

In The Name of God

Case Presentation

A 23 Y O Girl with Hamaturia

Patient Data:



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

A 23 Y o girl with
hamaturia (Not in
period time) and HTN
BP and azotemia: 160/90
Family history: Negative
Weakness, Paleness,
Headache




Anemia can cause fatigue, headaches, pale skin, and other symptoms.



A targeted approach
should be performed in
patients with an **unusual**
presentation of HTN
and Hematuria.

What is your Assessments?



Laboratory Tests

Electrolytes(Na, K, & serum Cr
(Calculate eGFR)

FBS

Urinalysis

Lipid profile (total-, HDL- & LDL-
Ch & TG)

ECG



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

Imaging



- Sonography
- Doppler Sonography
- CT Scan
- CT Angiography
- Angiography

Patient Data:



WBC: 6700, Hb: 10/5, Plt:

FBS: 98 mg/dl

BUN: 32 mg/dl, Cr: 2/6 m

U/A: Protein 2+, RBC: 10-12,

- *Red Urine & Common Cold was
Coincident*



Patient Data:

-Sonography

Normal

-Dysmorphic RBC was seen.



What is new assessments?

Na, K, IgA, HBSAg, HCVAb, HIVAb, Anti GBMAb, ANA, AntidsDNA, C3, C4, CH50, ANCA(P&C), Cryoglobulin, Urine Output,

-Sonography

-Doppler Sonography

& maybe...

-CT Scan?

-CT Angiography?

-Angiography?

-Kidney Biopsy?



Patient Data:



IgA titer is high and
Kidney biopsy show IgA
deposition in mesangium,
mesangial & endocapillary
hypercellularity



**IgA nephropathy is the
most common pattern of
primary
glomerulonephritis seen
in the Western world.**

Seminars in Nephrology

Volume 28, Issue 1, January 2008, Pages 27-37

Cases of
familial &
secondary IgA nephropathy
show
underlying genetic &
environmental triggers for this
disease.





Secondary IgA nephropathy
is seen most commonly in
patients with **liver disease** or
mucosal inflammation, in
particular affecting the **GI**
tract.



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

Dietary & microbial Ags have been identified in circulating **IgA immune complexes & mesangial IgA deposits**, suggesting that **environmental factors** may **play a role** in the pathogenesis of IgA nephropathy.

IgA nephropathy

- Present at any age
- Peak incidence: second & third decades of life.
- Male/female ratio: 2:1





قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

In a Chinese study of **13,519**
renal biopsies, **IgA**
nephropathy constituted
45% of all cases of primary
GN .

**IgA deposition does
not necessarily
followed by nephritis**



There are a number of reports documenting IgA deposition in other forms of GN include

- Thin basement membrane nephropathy,**
- Lupus nephritis,**
- Minimal Change Disease, &**
- Diabetic nephropathy.**



The
immunofluorescence
findings in IgA
nephropathy are
indistinguishable
from those in
**Henoch-Schönlein
purpura (IgA
vasculitis)**



Oxford classification of IgA nephropathy

- Mesangial hypercellularity
- Segmental glomerulosclerosis
- Endocapillary hypercellularity
- Tubular atrophy / interstitial fibrosis



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

CLINICAL FEATURES



قطب علمی آموزشی نفرولوژی مرکز تحقیقات نفرولوژی

Visible hematuria (40-50%) usually following an upper respiratory infection (**synpharyngitic hematuria**), bacterial tonsillitis, or by other viral upper respiratory infections even with tonsillectomy.

Low-grade fever

Microscopic hematuria (30-40%)

Less than 10 % nephrotic syndrome or acute RPGN

Rarely, AKI with or without oliguria.

IgA nephropathy

Transmitted as an

autosomal dominant trait

with incomplete

penetrance.

CLINICAL ASSOCIATIONS

- Cirrhosis and other forms of severe liver disease
- Celiac disease
- HIV infection
- Minimal change disease and membranous nephropathy
- Wegener
- Dermatitis herpetiformis,
- Seronegative arthritis (particularly ankylosing spondylitis),
- Small-cell carcinoma,
- Lymphoma (Hodgkin's lymphoma and T-cell lymphomas, including mycosis fungoides),
- Disseminated TB,
- Bronchiolitis obliterans, and
- IBD



Treatments

Nonimmunosuppressive (ACEis or ARBs, and fish oil).

Immunosuppressive therapy
(Glucocorticoids &...)



Isolated hematuria & minimal proteinuria (<500-1000 mg/day), & normal GFR are typically not treated & often not biopsied.

This group periodically monitored at 6-12 month intervals for increases in proteinuria, BP & Cr.



Proteinuria >500-1000 mg/d



A slightly reduced GFR that is not declining rapidly & only mild to moderate histologic findings on renal biopsy are **initially managed with nonimmunosuppressive (ACE i or ARB)**.

The goal is urine protein <500- 1000 mg/day & BP <130/80 mmHg.

Fish oil (3.3 g/d or more) can be tried in proteinuria >1g/d despite 3-6 mo of therapy with an ACEi or ARB.

Glucocorticoids recommended in **active disease (hematuria** in addition to one or more of the following):

- Increasing Cr
- Proteinuria >1 g/d after maximal antiproteinuric nonimmunosuppressive therapies
- Morphologic evidence of active disease in kidney biopsy (proliferative or necrotizing glomerular changes)



Glucocorticoid Therapy



IV methylprednisolone, 1 g, for 3 consecutive days at the beginning of months 1, 3, and 5, combined with 0.5 mg/kg of oral prednisolone given on alternate days for 6 months.

Or

Prednisone, 0.8 to 1 mg/kg/day, for 2 months followed by monthly dose reductions of 0.2 mg/kg/day during the next 4 months).

Or

Combined immunosuppressive therapy can be considered in patients with more severe disease as defined by a more rapidly progressive clinical course and/or histologic evidence of severe active inflammation.

Occasionally IgA nephropathy present with **nephrotic syndrome**, **no hematuria**, **NL kidney function**, **minimal glomerular changes on light microscopy** & **diffuse fusion of the foot processes of the glomerular epithelial cells on electron microscopy**.

These histologic findings are characteristic of **minimal change disease**.



